Abbott to Collaborate with Astellas in CMV Vaccine Trial
September
06, 2012 Abbott Park, Illinois (NYSE: ABT) — Abbott announced today
that it has signed an agreement to collaborate with Astellas Pharma
Global Development in a Phase 3 clinical trial
for ASP0113 (TransVax™), an investigational vaccine licensed from Vical
Incorporated for preventing cytomegalovirus (CMV) reactivation in
transplant patients. Read more
Post a Comment